BIOLINERX Ltd/S (BLRX) Releases Earnings Results, Meets Estimates
BIOLINERX Ltd/S (NASDAQ:BLRX) issued its earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.06), Morningstar.com reports.
Shares of BIOLINERX Ltd/S stock traded down $0.01 during midday trading on Friday, hitting $0.70. The company’s stock had a trading volume of 391,694 shares, compared to its average volume of 1,728,884. The stock has a market cap of $78.77 million, a PE ratio of -2.59 and a beta of 0.87. BIOLINERX Ltd/S has a 1-year low of $0.67 and a 1-year high of $1.84.
A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd bought a new position in BIOLINERX Ltd/S (NASDAQ:BLRX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned 1.27% of BIOLINERX Ltd/S as of its most recent SEC filing. Institutional investors own 34.69% of the company’s stock.
About BIOLINERX Ltd/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Featured Article: How are the companies in the S&P 500 selected?
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.